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Abstract
Determining the extent to which a patient is benefiting from cancer therapy
is challenging. Criteria for quantifying the extent of “tumor response” observed
within a few cycles of treatment have been established for various types of solid
as well as hematologic malignancies. These measures comprise the primary end-
points of phase II trials. Regulatory approvals of new cancer therapies, how-
ever, are usually contingent upon the demonstration of superior overall survival
with randomized evidence acquired with a phase III trial comparing the novel
therapy to an appropriate standard of care treatment. With nearly two thirds
of phase III oncology trials failing to achieve statistically significant results, re-
searchers continue to refine and propose new surrogate endpoints. This article
presents a Bayesian framework for studying relationships among treatment, pa-
tient subgroups, tumor response and survival. Combining classical components
of mediation analysis with Bayesian model averaging (BMA), the methodology
is robust to model mis-specification among various possible relationships among
the observable entities. Posterior inference is demonstrated via application to a
randomized controlled phase III trial in metastatic colorectal cancer. Moreover,
the article details posterior predictive distributions of survival and statistical met-
rics for quantifying the extent of direct and indirect, or tumor response mediated,
treatment effects. Keywords:Bayesian Model Averaging; Mediation analysis; On-
cology; Surrogate markers
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1 Introduction
The drug development paradigm for oncology was founded on a sequence of phases
with trials devised to elucidate various properties of novel agents and compare them to
current standard-of-care therapies. Dose selection takes place in phase I with a small
trial (< 50 patients), often with a dose escalation trial designed to estimate rates of
dose-limiting toxicity and identify an appropriate treatment dose. This is followed by
one or more moderately sized phase II trials (50 to 200 patients) devised to estimate
the preliminary clinical activity of the novel treatment using endpoints that emphasize
morphological and/or pathological changes to the primary disease site usually observed
within a few cycles following treatment (Eisenhauer et al., 2009; Hallek et al., 2018).
Given success in phase II, a randomized phase III trial is conducted, often to interrogate
whether a survival advantage may be attributable to the novel therapy when compared to
therapies used in routine clinical practice. Traditionally required for regulatory approval
of new therapies, phase III trials often enroll hundreds of patients and span multiple
clinical sites, and thus require substantially more investment in resources and time.
Implicit to this paradigm is the assumption that failure in phase II connotes failure
in phase III. Following a successful phase II trial, however, success in phase III remains
uncertain in most oncology settings. In fact, Hay et al. (2014) assert that only 28.3% of
the oncology Phase II trials successfully advanced to Phase III, which is lower than the
rate (34.8%) among non-oncology phase II studies. Success rates among phase III trials
(as defined by any FDA regulatory approval) are also lower for oncology trials (37%)
when compared to non-oncology drugs (54%). Thus, phase II trials are limited with
respect to the extent to which their results determine the eventual regulatory success of
putatively promising new cancer therapies. Explanations for the lack of predictive power
from phase II to subsequent success in phase III remains a relevant issue in oncology. It is
perhaps elevated in its importance with the continually evolving regulatory landscapes.
Changes in recent years at the US Food and Drug Administration (FDA) have yielded
pathways for Breakthrough Therapy designation, established by the FDA Safety and
Innovation Act (US Food and Drug Administration., a,b) as well as a pathway for
tissue-agnostic approvals spanning multiple previously disparate indications (Pestana
et al., 2020). Moreover, multiple stakeholders have promoted innovations and efficiency
in oncologic drug development with master protocol (Beckman et al., 2016; Woodcock
and LaVange, 2017; Wages et al., 2017; Hobbs et al., 2018; Kaizer et al., 2019) and
seamless designs (Prowell et al., 2016; Hobbs et al., 2019), as well as the integration of
real-world evidence (Griffith et al., 2019; Khozin et al., 2019).
If phase II trials are to become better harbingers of subsequent regulatory success
in oncology, trialists should prioritize endpoints that are established surrogate markers
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of survival (Buyse et al., 2010). Moreover, statistical criteria for trial success should
be informed by mediation models applied to parse the indirect effects of competing
therapies with respect to potential surrogate endpoints from direct effects of treatment.
Mediation analysis methodology was proposed to decompose the effects of interven-
tions into direct and indirect effects (Baron and Kenny, 1986). In the context of onco-
logic drug development, the indirect effect defines the extent of survival benefit that is
achieved from localized reductions in tumor burden (e.g. shrinking a solid tumor to a
certain extent), while direct treatment effects characterize the extent of survival benefit
attributable to all other factors not directly measured by the surrogate tumor response
endpoint. Statistical models for mediation analysis provide criteria for measuring the
extent to which any measure of tumor response yields a reliable surrogate for survival,
which is determined by the magnitude of indirect effect. A diagram describing these
relationships can be found in Figure S1 in the supplementary materials.
Several authors have proposed statistical models for mediation analysis and/or test-
ing for the mediation effect from the frequentist paradigms (Fairchild and MacKinnon,
2009; MacKinnon et al., 2002; Zhang et al., 2009; Mallinckrodt et al., 2006; Ho et al.,
2001). A few researchers have developed Bayesian models for inference of mediation
effects (Yuan and MacKinnon, 2009; Wang and Preacher, 2015; Nuijten et al., 2015).
All models previously proposed have assumed that both the mediator and patient
outcome were continuous variables. In this context, mediation effects can be derived
on the basis of linear and Gaussian formulations. Mediation analysis with survival
outcomes have been less common. VanderWeele (2011) described decompositions on
different outcome scales and gave formulae for calculating the mediation effects under
additive hazard, accelerated failure time, and rare-outcome proportional hazards mod-
els. Tchetgen (2011) proposed theory pertaining to estimation of natural direct and
indirect effects with marginal structural Cox proportional hazards model and additive
hazards model. Fulcher et al. (2017) discussed the effect of censoring and truncation
with respect to “product” and “difference” methods used to estimate the mediation ef-
fect under the accelerated failure time model. Lin et al. (2017) described methodology
for estimating mediation effects under a time-varying survival model. Considering the
oncology context, Vandenberghe et al. (2018) decomposed the total risk ratio, or ratio
of survival probabilities for treatment versus control, into the natural direct and indirect
effects. These derivations yield the mediation proportion, a metric characterizing the
relative magnitude of indirect effect.
The methods mentioned previously for survival outcomes arise from the frequentist
paradigm. This article presents a Bayesian framework for studying relationships among
treatment, patient subgroups, tumor response and survival. Bayesian model averag-
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ing (BMA) is a modeling technique which acknowledges uncertainty in model selection
(Hoeting et al., 1999). Facilitating robust analyses, BMA extends posterior inference
to the model space yielding integrative parameter estimates (Wasserman et al., 2000;
Fragoso et al., 2018). The methodology combines classical components of mediation
analysis with BMA, which provides robustness to model mis-specification among re-
lationships of the observable components aforementioned. Computation of this model
leverages reversible jump Markov chain Monte Carlo (RJMCMC). Algorithms for im-
plementation of RJMCMC, using the R package “nimble” (de Valpine et al., 2017), as
well as calculation of risk ratios and mediation proportion that define the extent to
which a treatment effect for survival is passed through objective response of tumor are
described in detail. Trialists and sponsors may lack sufficient data as well as a statistical
toolbox for designing phase III trials as a function of a drugs performance with respect
to surrogate endpoints measured in early phase trials. The article additionally explains
how the resultant posterior predictive distributions can be applied to predict the success
of ongoing studies at interim analyses or new trials when informed by historical data
sources. In the presence of low predictive power, a trial could be halted thereby saving
time, cost, and most importantly allowing trial participants to pursue alternatives.
The remainder of this article proceeds as follows. Section 2 describes the method-
ological framework for mediaton analysis with BMA. Methods for estimation based on
RJMCMC are described in Section 2.1. Tools for evaluating the mediation effect of
tumor response are discussed in Section 2.2 with their implementation detailed in Sec-
tion 2.2.1. Algorithms for prediction are presented in Section 2.3. Section 3 defines the
methods performance via simulation study and Section 4 applies the methodology to a
colorectal cancer study. Section 5 provides discussion.
2 Methodology
The mediation model for treatment, short-term tumor response and long-term sur-
vival outcome has two components: a logistic regression model for the tumor response
and a proportional hazards (PH) model (Cox, 1972) for the survival outcome. Let Y
denote the binary tumor response outcome with Y = 1 indicating response and 0 oth-
erwise. Treatment arm indicator A has two possible values 0 and 1 representing control
and treatment groups, respectively. X is a set of baseline covariates that need to be
adjusted in the model, such as subgroups of the patient population. We model the
log-odds of pi = Pr(Y = 1) as the linear combination of the predictors
logit(pi) = Drβ,
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where Dr is the design matrix in the response model and β is the corresponding vector
of coefficients. For example, a full model with treatment A, covariate X and their
interactions has linear predictor Drβ = β0 + β1A+ β2X + β3A×X.
The overall survival (OS) time T is the outcome of interest in the long-term study,
and a PH model is assumed here:
h(t|A, Y,X) = h0(t)× exp {Dsγ},
where h0(·) is the baseline hazard function. For example, assuming the Weibull(ν, λ)
distribution yields the following baseline hazard h0(t) = νλt
ν−1. Ds is the design matrix
in the survival model with coefficient vector γ. A full model containing treatment A,
response Y , covariate X and their pairwise interactions leads to Dsγ = γ1A + γ2Y +
γ3X + γ4A× Y + γ5A×X + γ6X × Y .
2.1 Estimation methods using RJMCMC
Let θ = (β,γ, ν, λ) denote the vector of unknown parameters in the mediation
models. We estimate the mediation model under the Bayesian framework and adopt
the reversible jump Markov chain Monte Carlo (RJMCMC) (Green, 1995) to get the
posterior samples for θ. RJMCMC is a general framework for MCMC simulation and it
can be viewed as an extension of the Metropolis-Hastings algorithm to more general state
spaces of varying dimensions. The advantage of RJMCMC is to avoid mis-specification
of the linear predictors in either the response or the survival models.
To illustrate all possible models we considered in our problem, we introduce indicator
vectors z = (z1, z2, z3) and w = (w1, · · · , w6) in the response and survival models,
respectively. The idea is that “removing a variable from the model is equivalent to
multiply its coefficient by zero, and only variables with non-zero indicators are included
in the model. Here, we list the indicator vectors for all possible response and survival
models in Table 1. In each model, the components with values of 1 are in the model
and 0 otherwise. For example, the response model R1 has coefficient z
′β = β0, where
z′ = (1, z), and is the null model with only the intercept included in the linear predictor.
We follow the hierarchical structure rules when specifying the models, that is, if the
interaction term is included in the model then the individual variables of the interaction
are included as well.
We assume flat priors for the parameter θ. Priors for β and γ are set to be inde-
pendent Normal distribution with zero mean and standard deviation of 100. The two
Weibull parameters ν and λ have Gamma prior with shape and rate equal to 0.001.
The indicators z and w have Bernoulli priors with probabilities ψz and ψw. To
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Table 1: Indicator vectors for all possible models
Response models
var. Int. A X A×X
Model coef. β0 β1 β2 β3
# indc. z1 z2 z3
R1 1 0 0 0
R2 1 1 0 0
R3 1 0 1 0
R4 1 1 1 0
R5 1 1 1 1
Survival models
var. A Y X A× Y A×X X × Y
Model coef. γ1 γ2 γ3 γ4 γ5 γ6
# indc. w1 w2 w3 w4 w5 w6
S1 0 0 0 0 0 0
S2 1 0 0 0 0 0
S3 0 1 0 0 0 0
S4 0 0 1 0 0 0
S5 1 1 0 0 0 0
S6 1 0 1 0 0 0
S7 0 1 1 0 0 0
S8 1 1 0 1 0 0
S9 1 0 1 0 1 0
S10 0 1 1 0 0 1
S11 1 1 1 0 0 0
S12 1 1 1 1 0 0
S13 1 1 1 0 1 0
S14 1 1 1 0 0 1
S15 1 1 1 1 1 0
S16 1 1 1 1 0 1
S17 1 1 1 0 1 1
S18 1 1 1 1 1 1
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maintain the hierarchical structures, we set up the following constraints on the indicators:
z1 × z2 ≥ z3,
w1 × w2 ≥ w4,
w1 × w3 ≥ w5,
w2 × w3 ≥ w6.
Under these constraints, values for ψz and ψw can be searched to obtain equal or
weighted model probabilities. For example, the reverse order of the model Akaike infor-
mation criterion (AIC) values can be used as the weight in selecting ψz and ψw. The
implementation and detailed algorithms using the “nimble” package can be found in
Supplementary materials.
The posterior model probabilities can be calculated based on the posterior samples
of z and w. By matching different combinations of the indicators to the corresponding
models in Table 1, we can count the frequencies of each model appears in the posterior
samples and calculate the proportions as the posterior model probabilities. We consider
a model with higher posterior probability is more likely to be the true model based on
observed data and the priors.
2.2 Risk ratio measures and mediation proportion
Under the mediation analysis framework, potential outcomes or counterfactual nota-
tions are very useful in describing the relationships among treatment, mediators and out-
comes. Here we assume the counterfactual variables Yi(a) and Ti(a) exist for each patient
i = 1 · · · , n, and each treatment arm a = 0, 1. With these notations, we have the regular
survival probabilities S(t|Ai = 1, Yi(1)) and S(t|Ai = 0, Yi(0)) for patients in treatment
and control groups, as well as the counterfactual survival probability S(t|Ai = 1, Yi(0))
for a patient who was assigned to the treatment group, but with the response outcome
the patient would have had been in the control group.
Vandenberghe et al. (2018) defined the natural direct and indirect treatment effects
on the survival outcomes based on the “risk ratios”, which are ratios of survival probabil-
ities. The risk ratio for total treatment effect is simply the ratio of survival probabilities
for treatment and control groups:
RRtot(t) =
S(t|Ai = 1, Yi(1))
S(t|Ai = 0, Yi(0)) .
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The risk ratio for direct treatment effect is defined as
RRd(t) =
S(t|Ai = 1, Yi(0))
S(t|Ai = 0, Yi(0)) ,
which reflects the direct treatment effect when holding the mediation effect of the re-
sponse at value Yi(0). The risk ratio for the natural indirect effect is defined as
RRm(t) =
S(t|Ai = 1, Yi(1))
S(t|Ai = 1, Yi(0)) ,
since it represents what would happen to a patient in the treatment arm when the
mediated effect through response changes from Yi(1) to Yi(0). Note that we have the
product of the direct and indirect risk ratios equals the risk ratio for the total effect.
The risk ratios defined above are ratios of survival probabilities, and they can be
very extreme as survival probabilities approach zero when time t increases. Instead,
we use the log versions of these risk ratios, which are the difference of the log survival
probabilities.
The mediation proportion is defined based on the risk ratios as
Med%(t) =
RRtot(t)−RRd(t)
RRtot(t)− 1 =
S(t|Ai = 1, Yi(1))− S(t|Ai = 1, Yi(0))
S(t|Ai = 1, Yi(1))− S(t|Ai = 0, Yi(0)) .
This quantity is not restricted between 0 and 1, but is valuable to evaluate the mediation
effect of response when the treatment effect on survival is positive.
2.2.1 Calculate logRRs based on posterior samples
Note that the risk ratios and mediation proportion defined above are all functions of
time. In practice, we make conclusions for specific time points t˜ = (t1 < t2 < · · · < tτ ).
Logarithm of risk ratios and their pointwise credible intervals are calculated as follows:
Assume we keep M posterior samples for θ after burn-in. For the mth set of samples
θ(m) = (β(m),γ(m), ν(m), λ(m)), m = 1, · · · ,M ,
Step 1. We calculate the predicted survival probabilities for each subject in the
data and at each time point t ∈ t˜. For example, with the Weibull(ν, λ) baseline
distribution, we have
S(m)(t|A, Y,X) = exp {−λ(m)tν(m) × eDsγ(m)}, (1)
where Ds is the full design matrix in the survival model based on the data.
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Step 2. Separate the above predicted survival probabilities based on treatment
group A and calculate the average as the mean survival for each group:
S
(m)
0 (t) =
1∑n
i=1 I(Ai = 0)
n∑
i=1
I(Ai = 0)S
(m)(t|Ai, Yi, Xi),
S
(m)
1 (t) =
1∑n
i=1 I(Ai = 1)
n∑
i=1
I(Ai = 1)S
(m)(t|Ai, Yi, Xi).
Step 3. Construct the artificial design matrix D∗s by assuming all subjects are in
the treatment group. Calculate S
(m)
∗ (t|A = 1, Y,X) by replacing Ds with D∗s in
Equation (1). The counterfactual survival probabilities are calculated by taking
the average of this quantity for subjects in the control group:
S(m)∗ (t) =
1∑n
i=1 I(Ai = 0)
n∑
i=1
I(Ai = 0)S
(m)
∗ (t|Ai = 1, Yi, Xi).
Step 4. Repeat the above steps 1-3 for each set of posterior samples, and calculate
the log risk ratios and mediation proportion by taking the average of the samples
as follows:
l̂RRtot(t) =
1
M
M∑
m=1
log(S
(m)
1 (t))− log(S(m)0 (t)),
l̂RRd(t) =
1
M
M∑
m=1
log(S(m)∗ (t))− log(S(m)0 (t)),
l̂RRm(t) =
1
M
M∑
m=1
log(S
(m)
1 (t))− log(S(m)∗ (t)),
M̂ed%(t) =
1
M
M∑
m=1
S
(m)
1 (t)− S(m)∗ (t)
S
(m)
1 (t)− S(m)0 (t)
.
Step 5. Derive the 95% pointwise credible intervals by finding the 2.5% and 97.5%
quantiles of the samples for each quantity.
2.3 Posterior Predictive Power
This section demonstrates how Bayesian posterior predictive computation can be
used to predict whether a trial will achieve a statistically significant result upon com-
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pletion. More specifically, the Bayesian framework yields predictive distributions of un-
observed survival durations for censored patients and future trial participants. Through
repeated sampling from these densities and application of statistical testing procedures
to the predicted outcomes, it is possible to obtain posterior predictive densities that
reflect the current expectation for treatment comparison that will result at the end of
the trial. This section describes this process using the log-rank test as the basis for
treatment comparison.
Consider two situations for prediction: 1) using historical data to estimate power
of future studies; and 2) predict success of a trial at an interim analysis. In the first
situation, we have a complete historical data with all the response and survival outcomes,
while no data are available for the new study. In the other case, we have partial data
available at an interim analysis of an onging trial. The partial data is used to predict
the survival outcomes for new patients and patients who had not yet failed by that time.
Let Oc = (Tc, δc,Yc,Ac,Xc) denote the current observed data. We estimate the
parameter θ based on Bayesian mediation models and obtain M posterior samples:
θ̂(1), · · · , θ̂(M). Let Op = (Ap,Xp) be the test data with only treatment assignments
Ap and baseline covariates Xp. We first discuss below the algorithm for calculating the
prediction power for the test data alone.
For the posterior sample θ̂(m),m = 1, · · · ,M ,
Step 1 Predict the response outcome:
– S1.1: We calculate the linear predictor terms Dpr β̂
(m) in the response model,
where Dpr is the design matrix constructed based on the test data O
p.
– S1.2: The response probability vector is pi(m) = exp (Dpr β̂
(m))/[1+exp (Dpr β̂
(m))].
The predicted response outcome is generated as Y
(m)
p ∼ Bernoulli(pi(m)).
Step 2 Predict the survival outcome:
– S2.1: Calculate the linear predictor terms in the survival model D
p,(m)
s γ̂(m),
where D
p,(m)
s is the design matrix constructed based on the test data Op and
the predicted response Y
(m)
p from previous step.
– S2.2: Generate the predicted survival time T
(m)
∗ from the survival model
h(t|θ̂(m),Op,Y (m)p ) = ν(m)λ(m)tν
(m)−1 × exp {Dp,(m)s γ̂(m)}.
– S2.3: Generate censoring time C according to the study design. For example,
if the study stops at a landmark time c, we have C ≡ c. The predicted survival
outcome is then calculated as T
(m)
p = min (T
(m)
∗ ,C) and δ
(m)
p = I(T
(m)
∗ ≤ C).
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Step 3 Perform the log-rank test on the predicted survival outcomes in Step 2
with respect to treatment group Ap and record the p-value p
(m).
Step 4 Repeat Steps 1-3 for m = 1, · · · ,M and record the test results as p =
(p(1), · · · , p(M)). Calculate the power as the proportion of significant p-values at
level α.
The above algorithm is for predicting the power for a new test data. This fits the first
situation we discussed when we would like to do prediction based on historical data. In
the second situation, we do estimation on the partial data at interim, but would like to
predict the power for the final complete data. We follow the same steps 1-2 to generate
predicted response and survival outcomes, but perform the log-rank test on the combined
data O(m) = (Oc,Op,(m)), where Op,(m) = (T
(m)
p , δ
(m)
p ,Y
(m)
p ,Ap,Xp) is the test data O
p
with predicted outcomes generated based on θ(m).
Sometimes we may have collected some response outcomes Yp for the test data O
p,
but no one has had the event yet. In that case, we can skip Step 1 and predict survival
outcomes based on Op1 = (Yp,Ap,Xp).
3 Simulation
We have performed extensive simulations to further evaluate the operating character-
istics of the proposed BMA-based mediation model. We generated data for the proposed
mediation models:
logit{Pr(Y = 1)} = β0 + β1A+ β2X + β3A ·X,
h(t|A, Y,X) = h0(t)× exp {γ1A+ γ2Y + γ3X + γ4A · Y + γ5A ·X + γ6X · Y },
where the baseline hazard function had Weibull(ν, λ) distribution h0(t) = νλt
ν−1. The
true values for the Weibull parameters were set at ν = 2 and λ = 1. Subjects were
assigned to treatment (A = 1) or control (A = 0) group with 1:1 ratio. Covariate X was
generated from Uniform(-2, 4) distribution.
The survival time was subject to right censoring. A prespecified landmark time point
c = 1.2 was assumed, and subjects with survival time exceeded c was treated as right
censored. The resulted censoring proportions in the four scenarios below are around
31.14%, 23.55%, 26.66% and 20.61%, respectively.
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3.1 Simulation designs
We consider four scenarios for the relationships among treatment, response and sur-
vival outcomes. In Scenario I, we assume the treatment only has indirect effect on
survival through response, and the direct treatment effect on survival is zero. The co-
efficients are set to be β = (1, 2,−1, 2) and γ = (0,−0.84, 1, 0, 0, 0). The corresponding
response and survival models are R5 and S7. Under this assumption, we should have
the total effect equals the mediated effect (lRRtot = lRRm) and mediation proportion
equals 1.
We make the other extreme assumption in Scenario II, where mediation effect through
response is zero. The coefficients are set to be β = (1, 0,−1, 0) and γ = (−0.4, 0, 1, 0, 0, 0).
The corresponding response and survival models are R3 and S6. The total treat-
ment effect equals direct effect lRRtot = lRRd and the mediation proportion is zero.
We consider the most common case in Scenario III, where treatment has both direct
and indirect effects on survival. The coefficients are set to be β = (1, 2,−1, 2) and
γ = (−0.65,−0.6, 1, 0, 0, 0). The corresponding response and survival models are R5
and S11. All the log risk ratios are positive and the mediation proportion is between 0.2
and 0.4 under this setting.
Finally, in Scenario IV, we consider a situation where we observe treatment effect on
the response outcome, but neither treatment nor response has any effect on the survival
outcome. The coefficients are set to be β = (1, 2,−1, 2) and γ = (0, 0, 1, 0, 0, 0). The
corresponding response and survival models are R5 and S4. All of the log risk ratios are
equal to zero and the mediation proportion cannot be calculated in this case. The true
survival curves for the treatment and control groups under each scenario can be found
in online supplementary materials (Figure S2). Based on the specified coefficients, the
hazard ratios comparing control with treatment groups are around 1.5 for the first two
scenarios, 2.5 for the third scenario and 1 in the last case.
3.2 Simulation results
We used sample size n = 1000 (treatment and control arms combined) in our simu-
lation and conducted 100 replications for each setting. Results for a smaller sample size
of n = 500 were provided in supplementary materials for comparison. For the MCMC
procedure, we used two chains with each having 10,000 samples and dropped the first
5000 generated during the burn-in period. No thinning was made for the samples. We
used the reverse order of AIC as the weight to calculate the prior probabilities ψz and
ψw for the indicator variables.
Summary of the estimated regression coefficients are presented in Table 2, where we
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report the bias, mean of the standard deviation (MStd) and the coverage probability
(CP) of the 95% Highest Posterior Density (HPD) intervals. For the proposed method,
the bias of all the parameters are small and the CP is close to the nominal level 0.95.
The posterior model probabilities were summarized in Table 3 for each setting. The
average of the model probabilities were calculated with the minimum and maximum
values in parenthesis. True models numbers were listed in the parenthesis after each
scenario and we could see the true models always have the highest posterior model
probabilities in all settings.
In Figure 1, the average of the mean log risk ratios were plotted in dashed lines and
compared with the true curves in solid lines. The 2.5% and 97.5% quantiles of the mean
log risk ratios were added as dotted lines in the plots. The estimated log risk ratio curves
were close to the truth in all of the four scenarios. The figures summarizing the mediation
proportions were in the online supplementary materials. The median values were close
to the truth for the first three scenarios while the mediation proportion calculated in
the last scenario was not applicable because all the risk ratios were equal to zero.
3.3 Predictive power for future studies
In previous sections, we showed that the proposed mediation model helps in calibrat-
ing the mediation effect of the short-term tumor response through estimation of the log
risk ratios and mediation proportions. Moreover, the estimated models can be applied
to predict the trial results. These predictions improve as tumor response confers more
information about the long-term survival of patients. Under each of the four scenar-
ios in Section 3.2, we calculated the prediction power for achieving success under two
cases: (a) use interim data to predict current trial and (b) use historical data to predict
future study. No response data is available for the future data. Different sample sizes
n = 200, 500 and 1000 were used for available data used for estimation.
We generated an independent dataset with sample size n2 = 100, 200, 300 and 500 for
the future study data. We pretended the response and survival outcomes were unknown.
The log-rank test was performed for the final analysis and the proportion of significant
test results was calculated as the power. Two-sided significance level α = 0.05 was
used. For case (a), the tests were performed on the combined data of previous and the
predicted survival outcomes, while in case (b), only predicted survival data were used.
The mean of the power curves under each scenario are plotted in Figure 2. Note that
the power in the last scenario is very low since there is no treatment difference between
the two groups by design. Otherwise, in general, the power increases as sample size
increases. Combining current data and predicted data leads to a higher power due to
larger total sample sizes.
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Table 2: Simulation study: summary of parameter estimates
par. Bias MStd CP Bias MStd CP
Scenario I Scenario II
β0 0.010 0.144 0.990 0.000 0.102 0.940
β1 0.219 0.357 0.910 -0.000 0.014 1.000
β2 -0.004 0.086 0.970 -0.002 0.060 0.980
β3 0.124 0.251 0.930 0.000 0.000 1.000
γ1 -0.003 0.012 1.000 -0.002 0.077 0.930
γ2 0.018 0.085 0.900 0.000 0.009 1.000
γ3 0.006 0.035 0.910 0.000 0.033 0.910
γ4 0.000 0.000 1.000 0.000 0.000 1.000
γ5 0.000 0.000 1.000 0.000 0.002 1.000
γ6 0.000 0.002 1.000 0.000 0.000 1.000
ν 0.007 0.061 0.890 0.004 0.058 0.960
λ -0.012 0.086 0.940 0.007 0.065 0.960
Scenario III Scenario IV
β0 0.028 0.146 0.930 0.029 0.145 0.940
β1 0.136 0.347 0.950 0.095 0.337 0.960
β2 -0.016 0.086 0.930 -0.020 0.087 0.940
β3 0.125 0.245 0.920 0.091 0.239 0.910
γ1 -0.017 0.116 0.910 -0.006 0.013 1.000
γ2 0.012 0.125 0.910 -0.003 0.012 1.000
γ3 0.004 0.036 0.930 0.002 0.032 0.960
γ4 0.001 0.010 1.000 0.006 0.007 1.000
γ5 0.000 0.003 1.000 0.000 0.000 1.000
γ6 0.000 0.002 1.000 0.000 0.000 1.000
ν 0.006 0.062 0.970 0.004 0.056 0.940
λ 0.004 0.095 0.910 0.012 0.055 0.960
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Table 3: Simulation study: posterior model probability summary (the true models in
each scenario are in the parenthesis)
Scenario I (R5&S7) Scenario II (R3&S6) Scenario III (R5&S11) Scenario IV (R5&S4)
Response model
R1 0 0 0 0
R2 0 0 0 0
R3 0 99.47(89.47,99.9) 0 0
R4 0 0.53(0.1,10.52) 0 0
R5 100(100,100) 0 100(100,100) 100(100,100)
Survival model
S1 0 0 0 0
S2 0 0 0 0
S3 0 0 0 0
S4 0 1.65(0,49.11) 0 97.49(49.54,99.71)
S5 0 0 0 0
S6 0 97.69(50.57,99.74) 3.85(0,97.46) 0.75(0.1,37.79)
S7 98.41(17.58,99.88) 0.02(0,1.2) 0.83(0,50.46) 1.24(0.13,40.69)
S8 0 0 0 0
S9 0 0.1(0,1.38) 0.01(0,1.23) 0
S10 0.12(0,2.52) 0 0 0
S11 1.46(0.09,81.73) 0.54(0.16,3.42) 94.51(2.47,99.85) 0.01(0,0.38)
S12 0.01(0,0.6) 0 0.4(0,14.34) 0.5(0,49.95)
S13 0 0 0.19(0,8.62) 0
S14 0 0 0.2(0,7.36) 0
S15 0 0 0 0
S16 0 0 0 0
S17 0 0 0 0
S18 0 0 0 0
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Figure 1: Estimated log Risk ratios under different simulation scenarios (I: indirect effect
only; II: direct effect only; III: both effects exist; IV: neither effect exist.)
The prediction ability of the model can be evaluated by looking at the relationship
between the predicted power and the actual log-rank test results on the new data.
We constructed the scatter plots with Spearman’s correlation coefficients and Receiver
Operating Characteristic (ROC) curves with area under the curves (AUCs) calculated
for each scenario as shown in Figures S5 - S8 in the online supplementary materials.
4 Analysis of a Colorectal Cancer Phase III Trial
Our research was motivated by a colorectal cancer study reported by Goldberg et al.
(2004). Seven hundred ninety five patients with metastatic colorectal cancer who had not
been treated previously for advanced disease were randomly assigned to receive irinote-
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Figure 2: Predicted power(I: indirect effect only; II: direct effect only; III: both effects
exist; IV: neither effect exist.)
can and bolus fluorouracil plus leucovorin (IFL), oxaliplatin and infused fluorouracil plus
leucovorin (FOLFOX), or irinotecan and oxaliplatin (IROX). FOLFOX and IROX were
two new regimens under investigation while IFL was considered as the standard of care.
The ordinal tumor response (progression disease (PD), stable disease (SD), partial re-
sponse (PR), and complete response(CR)) was assessed for each patient by the modified
Response Evaluation Criteria In Solid Tumors (RECIST) criteria Therasse et al. (2000)
every 6 weeks for the rst 42 weeks. Patients who received the FOLFOX regimen were
found to have better tumor response and progression-free survival when compared to
patients in the other two groups. It is not clear, however, whether the better survival
outcome in FOLFOX group was due to the better tumor response, or to what extent
tumor response conferred prolonged survival for this indication.
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To illustrate the proposed method, we restrict to the 531 patients who received either
the FOLFOX regime (treatment group) or the standard of care IFL (control group), and
compare their OS. Only 5.6% of the patients were right censored. The median survival
time in the FOLFOX was 594 days, which was longer than the median survival time of
441 days in the IFL group. We create the binary response outcome Y as follows: if a
patient had CR or PR as the best response outcome, we assign Y = 1; otherwise Y = 0.
One hundred thirty two (49.4%) patients in the FOLFOX group had response Y = 1
compared to 100 (37.9%) in the IFL group. Analyses were adjusted for baseline age
group (< 65 years old or ≥ 65). Age was imputed if missing by the mean age of the
patients in the same treatment group and with the same response outcomes. The trial
studied 183 (34.5%) patients older age 65 in the two groups.
The proposed mediation model was applied to the colorectal cancer data using the
RJMCMC algorithm. For the MCMC procedure, we used two chains with each having
20,000 samples. The first 10,000 samples were omitted from inference as burn-in. The
estimated regression coefficients and the posterior model probabilities can be found
in online supplementary materials. Based on the marginal model probabilities, the
null model (R1) and the model with only treatment effect (R2) constituted 72.9% and
26.9% of the samples in the response models. For the survival model, the majority of
posterior model probabilities lied in the model with only response (S3) and the model
with treatment and response (S5), which were 63.7% and 32.1%, respectively.
Figure 3 (a) presents Kaplan-Meier curves for survival by tumor response, which
exhibit clear ordering with respect to the magnitude of the surrogate. Figure 3 (b) de-
picts the median of the log risk ratios with their 95% highest posterior density (HPD)
intervals over time. The direct effect (red) is estimated to be close to zero, although it is
imprecisely estimated with larger variability. This results from the BMA among models
with differing characterizations of the direct effect. While advantageous is facilitating
robustness to model mis-specification, BMA can yield mixture posteriors with skewed
distributions. By way of contrast, the mediated effect (green) is estimated to be positive
with highly localized HPD interval, suggesting consistent estimation among averaged
models. As a result of the heterogeneous posterior for direct effect, the mediation pro-
portion (shown in the Supplementary materials Figure s9) has a bi-modal distribution
with median approximately 1 and mean around 0.7. Overall the results suggest that
reduction in tumor size following treatment conferred prolonged survival for the studied
patient population. Moreover, most of the treatment effect observed for survival was
mediated through tumor response.
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5 Discussion
Patient heterogeneity is a hallmark of oncology. Drug developers learning from
trial data encounter complex relationships among patient subpopulations, therapies,
response, and survival. This article presented a Bayesian framework for mediation anal-
ysis formulated to study tumor response and survival among competing therapies. The
article detailed algorithms for quantifying the strength of a surrogate marker for sur-
vival from the model’s posterior samples. Simulation studies demonstrated the method’s
performance in the presence versus absence of reliable surrogate markers and/or direct
treatment effects. Additionally, the method was applied to a randomized colorectal
cancer study devised to compare competing chemotherapeutic regimens with respect to
survival. The methodology proposed leverages Bayesian model averaging to facilitate ro-
bustness to mis-specification of modeling assumptions that impact statistical estimation
of subgroups, treatments, response, and their conjoint effects on survival. RJMCMC,
demonstrated using the R package “nimble”, facilitates full posterior inference and com-
putation of posterior predictive distributions of survival.
The reader should note a few limitations. The mediation models developed in this
article assumed binary tumor response in settings with two competing therapies. Exten-
sions to multifactorial responses require alteration of the regression model for response
to accommodate multinomial and/or ordinal distributional assumptions (Glonek and
McCullagh, 1995; O’brien and Dunson, 2004; Qaqish and Ivanova, 2006). For studies
with multiple treatment arms and a common control group, log risk ratios and mediation
proportion can be calculated for comparing each treatment group to the control. For ex-
ample, if we have three groups A ∈ {0, 1, 2} with A = 0 denoting the control group. We
need to calculate individual survival probabilities S(t|Ai = j, Yi(j)), j = 0, 1, 2, as well as
counterfactual survival probabilities S(t|Ai = j, Yi(0)), j = 1, 2. Thereafter, calculations
of risk ratios take place with respect to each treatment group j(j = 1, 2).
Survival distributions assumed a parametric Weibull baseline distribution and relies
on the proportional hazards assumption. The assumptions ensure an identifiable pa-
rameter space and facilitate fast convergence with BMA for posterior inference as well
as tractability for posterior predictions. Nonetheless, parametric families limit model
flexibility, especially in presence of high censoring. Extensions to semi-parametric mod-
els may extend the method to accommodate violations of Weibull forms (Hobbs et al.,
2013; Murray et al., 2015, 2016).
The selection of a surrogate marker of survival is challenging in oncology. Intro-
duced by Daniels and Hughes (1997), meta-analytic approaches are the gold standard
for evaluating surrogate markers. The method uses a series of studies to establish the
relationships between treatment, potential surrogate marker and the final endpoint. Sev-
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eral authors have considered and extended the framework (Gail et al., 2000; Bujkiewicz
et al., 2016; Papanikos et al., 2020). The method relies on aggregate data from different
trials, which may enroll potential diverse clinical populations. Moreover, fairly large
number of studies are needed before the results can be applied to a new study. Real-
world databases promise to provide additional avenues for data-driven exploration and
validation of surrogate markers.
Moreover, the reliability of a candidate surrogate may vary by clinical indication
and class-of-therapy. For traditional cytotoxic therapies, used as curative treatments,
it is often assumed that extensions in overall survival are proportional to reductions
in the primary tumor site. Recent trials of non-cytotoxic immunotherapies, however,
have yielded patients with prolonged survival in the absence of reductions in tumor size.
In response to this, alternative surrogate outcomes, such as duration of response, have
been proposed for this therapy class. With technological advances in cancer imaging
and emphasis on precision medicine, new surrogate endpoints promise to improve the
prevailing techniques (Subbiah et al., 2017). Extension of the current framework to
multiple surrogate outcomes warrants future investigation (Huang and Yang, 2017).
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Supplementary materials
Mediation model diagram
We study the relationships of treatment, tumor response and survival outcomes under
the mediation analysis framework in Figure 4. Based on this triangular framework,
treatment effect on the survival outcome can be decomposed into the indirect effect via
tumor response and the remaining direct effect.
Implementation of RJMCMC using “nimble” package
One challenge of implementation of RJMCMC is that the dimension of the parameter
space changes across different models. We use the R package “nimble”, whch allows a
combination of high-level processing in R and low-level processing in C++, to implement
the RJMCMC for the mediation models. We can write the models in NIMBLE language,
which is an extended version the BUGS language, and it will generate and compile the
C++ code for the models and assign default samplers for each node.
To implement RJMCMC in “nimble”, we combine the nodes for the coefficients β
and γ with their model indicator nodes z and w. This can be done by the in-built
function “configureRJ()”. As a result, the function is set up so that a coefficient will
only be estimated when the corresponding indicator value is non-zero.
To enforce the constraints on the indicators, “nimble” provides a general way us-
ing “dconstraint()”. For example, the constraint on z can be realized by specifying
“constraint1 ∼ dconstraint(z1 ∗ z2 ≥ z3)” in the model and setting constraint1 to 1 in
the data.
We propose to use the R package “nimble” and the following algorithm to obtain
posterior samples for parameter θ and and the indicators z and w:
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Step 1. Obtain the prior probabilities ψz and ψw based on preassigned model
weights. This can be achieved by minimizing the standard deviations of the model
probabilities divided by weights. We use “GenSA” package to find the optimized
values.
Step 2. Write down the model in “nimbleCode()” function. This contains three
parts:
2(a). Specify the prior distributions for each parameter in θ and the indicators
z and w.
2(b). Use dconstraint() to put constraints on the indicators.
2(c). Define the likelihood for the response and survival models.
Step 3. Build the model using the “nimbleModel()” function, and specify the
initial values.
Step 4. Create MCMC configuration use “configureMCMC()” function, which
assigns default samplers to each node based on the model definition.
Step 5. Apply RJMCMC using the “configureRJ()” function: connect the nodes
for the coefficients with the nodes for the corresponding indicators.
Step 6. Build the MCMC object for the modified samplers in Step 5 using the
“buildMCMC()” function and compile the model and MCMC using the “com-
pileNimble()” function.
Step 7. Draw MCMC samples for θ and the indicators using the “runMCMC()”
function. MCMC parameters can be specified here, such as number of chains and
the number of samples for burn-in and thinning.
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Table 4: Simulation study: summary of parameter estimates (n=500)
par. Bias MStd CP Bias MStd CP
Scenario I Scenario II
β0 0.020 0.207 0.970 0.010 0.145 0.960
β1 0.317 0.529 0.950 -0.001 0.024 1.000
β2 -0.034 0.124 0.930 -0.004 0.086 0.960
β3 0.200 0.371 0.960 -0.000 0.000 1.000
γ1 -0.009 0.023 0.990 0.062 0.136 0.860
γ2 -0.011 0.123 0.940 0.003 0.016 1.000
γ3 0.017 0.049 0.930 0.005 0.047 0.950
γ4 0.000 0.002 1.000 0.000 0.001 1.000
γ5 0.000 0.000 1.000 -0.001 0.003 1.000
γ6 0.000 0.003 1.000 0.000 0.000 1.000
ν 0.024 0.086 0.980 0.010 0.082 0.940
λ 0.013 0.126 0.930 -0.026 0.098 0.920
Scenario III Scenario IV
β0 0.004 0.206 0.950 0.081 0.211 0.940
β1 0.315 0.528 0.910 0.230 0.526 0.970
β2 -0.024 0.124 0.960 -0.058 0.127 0.960
β3 0.185 0.368 0.950 0.214 0.366 0.950
γ1 -0.010 0.211 0.750 0.001 0.012 1.000
γ2 0.050 0.203 0.720 -0.001 0.015 1.000
γ3 0.018 0.054 0.900 0.006 0.045 0.980
γ4 0.012 0.034 1.000 0.000 0.000 1.000
γ5 -0.003 0.008 1.000 0.000 0.000 1.000
γ6 0.000 0.002 1.000 0.000 0.000 1.000
ν 0.014 0.088 0.980 0.012 0.080 0.960
λ -0.033 0.139 0.790 0.003 0.075 0.940
More simulation results
Simulation designs
The true survival curves for the treatment and control groups are plotted in Figure 5.
Simulation results
Simulation results for smaller sample size n = 500 are listed in Table 4 and Table 5.
Comparing with the results for n = 1000 in the main article, the model selection is
better and the bias get smaller as sample size increases.
The median of the mediation proportions is calculated at each time point and plotted
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Table 5: Simulation study: posterior model probability summary (n=500)
Scenario I (R5&S7) Scenario II (R3&S6) Scenario III (R5&S11) Scenario IV (R5&S4)
Response model
R1 0 0 0 0
R2 0 0 0 0
R3 0 99.37(92.15,99.87) 0 0
R4 0 0.63(0.13,7.85) 0 0
R5 100(99.99,100) 0 100(100,100) 100(100,100)
Survival model
S1 0 0 0 0
S2 0 0 0 0
S3 0 0 0 0
S4 0 21.27(0,96.53) 0 97.8(47.5,99.65)
S5 0 0 0 0
S6 1.24(0,92.62) 76.82(0.4,99.67) 26.06(0,99.14) 1.15(0.09,48.17)
S7 97.7(4.08,99.77) 0.64(0,46.64) 18.15(0,98.35) 1.05(0.2,25.98)
S8 0 0 0 0
S9 0 0.49(0,38.39) 1.11(0,50.38) 0
S10 0.12(0,1.38) 0 0.03(0,0.89) 0
S11 0.89(0.21,15.27) 0.75(0.01,23.02) 53.27(0.5,99.65) 0.01(0,0.36)
S12 0.04(0,3.46) 0.02(0,2.29) 1.06(0,50.24) 0
S13 0 0.01(0,0.39) 0.23(0,5.77) 0
S14 0.01(0,0.97) 0 0.09(0,1.95) 0
S15 0 0 0 0
S16 0 0 0 0
S17 0 0 0 0
S18 0 0 0 0
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in dashed lines for sample size n = 500 (Figure 6) and n = 1000 (Figure 7). The truth
is plotted in solid red lines as reference in the plots. The dotted lines are the 2.5% and
97.5% quantiles of the estimated mediation proportion in the simulation. Note that the
first three scenarios have median values close to the truth, but the variation can be very
large in the first two scenarios, where we have extreme situations of either no direct
effect or no mediation effect. The mediation proportion calculated in the last scenario
does not make sense because all the risk ratios are equal to zero.
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Predicted power evaluation
The scatter plots of actual p-values and one minus predicted power for sample sizes
n = 500 and 1000 are presented in Figure 8 and 9, respectively. Since the relations are
not linear, we calculated the Spearman’s correlation coefficients for each one, and larger
correlation coefficients indicate better prediction ability of the model.
Another way to present the relationships between the predicted power and actual
p-values from log-rank tests is through ROC curves. We present the ROC curves and
calculate the area under the curve (AUC) in Figures 10 and 11 for sample sizes n = 500
and 1000, respectively. Larger value of AUCs is a indicator of good prediction ability
of the model. The sample sizes of new data has nothing to do with the AUCs, since
both the actual and predicted outcomes have more chance to be significant as sample
size increases. Due to the space limit, we only present the curves for prediction sample
size n2 = 200, other cases have similar results. The AUCs are above 0.75 most of the
time, indicating a fairly good prediction ability of the estimated model.
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Table 6: Summary of coefficient estimates for colorectal cancer study
Estimate Std 95% HPD
Response model
Intercept -0.3199 0.1457 -0.6347 -0.0772
Trt (FOLFOX) 0.1273 0.2286 0 0.6243
Age (≥ 65) -0.0002 0.0103 0 0
Trt×Age 0 0 — —
Survival model
ν 1.1698 0.0414 1.0914 1.2593
λ 0.0008 0.0002 0.0004 0.0013
Trt (FOLFOX) -0.0894 0.1348 -0.3551 0
Y -0.5136 0.0878 -0.6767 -0.3325
Age (≥ 65) 0.0079 0.0429 0 0
Trt×Y 0.0001 0.0054 0 0
Trt× Age 0 0 — —
Age×Y 0 0.0018 0 0
Table 7: Posterior model probabilities for colorectal cancer study
S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 − S18 RowSums
R1 0 0 46.58 0 23.27 0 1.83 0.09 0 0.01 1.18 0 72.94
R2 0 0 17.06 0 8.82 0 0.51 0.03 0 0 0.45 0 26.86
R3 0 0 0.08 0 0.06 0 0 0 0 0 0 0 0.13
R4 0 0 0.05 0 0.02 0 0.01 0 0 0 0 0 0.07
R5 0 0 0 0 0 0 0 0 0 0 0 0 0
ColSums 0 0 63.76 0 32.15 0 2.35 0.11 0 0.01 1.63 0
Additional information on real data analysis
We list the estimated regression coefficients in the mediation models in Table 6 and
the posterior model probabilities in Table 7. Based on the marginal model probabilities,
we see that in the response model, the null model (R1) and the model with only treatment
effect (R2) constitute 72.9% and 26.9% of the samples. In the survival model, the mass
of the posterior model probabilities lies in the model with only response (S3) and the
model with treatment and response (S5), which are 63.7% and 32.1%, respectively.
The distribution of the estimated mediation proportion is summarized in Figure 12.
The mean curve in solid line is around 0.7 and the quantiles above 0.4 are equal to 1.
Lower quantiles are marked with dashed lines in the figure.
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(a) Kaplan-Meier curves by response outcomes
(b) log Risk ratios
Figure 3: Colorectal cancer study ((a): CR = complete response, PR = partial response,
SD = stable disease and PD = progressive disease; (b) shows the median (solid line)
and 95% HPD intervals (dashed lines) of the estimated log risk ratios).
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Figure 4: Mediation model diagram
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Figure 5: True survival curves under different scenarios (I: indirect effect only; II: direct
effect only; III: both effects exist; IV: neither effect exist.)
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Figure 6: Estimated mediation proportions under different scenarios for n = 500 (I:
indirect effect only; II: direct effect only; III: both effects exist; IV: neither effect exist.)
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Figure 7: Estimated mediation proportions under different scenarios for n = 1000 (I:
indirect effect only; II: direct effect only; III: both effects exist; IV: neither effect exist.)
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Figure 8: Scatter plots for p-values and predicted power (n=500)
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Figure 9: Scatter plots for p-values and predicted power (n=1000)
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Figure 10: ROC curves for evaluating prediction ability of the models for n = 500 (I:
indirect effect only; II: direct effect only; III: both effects exist; IV: neither effect exist.)
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Figure 11: ROC curves for evaluating prediction ability of the models for n = 1000 (I:
indirect effect only; II: direct effect only; III: both effects exist; IV: neither effect exist.)
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Figure 12: Distribution of mediation proportions over time (mean in solid line and
marked quantiles in dashed lines)
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